As more American consumers get on GLP-1 drugs, retailers are spotting a new opportunity to boost clothing sales by up to $13 billion annually. That's because millions of Americans are experiencing dramatic body size changes, and retail experts are seeing early clues of how this may play out. For one, sales of bigger bras are falling.The first step of what could translate to many other clothing categories, personal styling service Stitch Fix has already seen a jump in the number of customers that are mention ...

From @WSJopinion: Will GLP-1 drugs transform the food business? Probably not. People are likely to eat smaller and fewer meals, but not necessarily healthier ones, writes Roland Fryer.https://t.co/uILCicEs8h ...

Whether those now taking GLP-1 drugs preventatively will live to regret doing that or, conversely, will live long enough not to, remains to be seen https://t.co/5p47Mu7SJeIllustration: Cristina Spanò https://t.co/mJd3A4XcPb ...

Novo Nordisk is targeting Japanese patients willing to pay out-of-pocket for GLP-1 drugs such as Wegovy https://t.co/NQyHCefLpD ...

Core Insights - Eli Lilly has launched the Employer Connect program, offering its GLP-1 drug Zepbound at a fixed net price of $449 per month, significantly below the list price of over $1,000, which is expected to drive revenue growth [1][7][9] - The company forecasts a 25% revenue growth for 2026, driven by the new program and the upcoming launch of oral tirzepatide, which shows superior efficacy compared to competitors [1][13][14] Company Strategy - Eli Lilly is establishing a strong lead in the GLP-1 market through superior clinical efficacy of tirzepatide and a direct-to-employer distribution model that bypasses pharmacy benefit managers [2][11] - The Employer Connect program partners with over 15 independent administrators, providing comprehensive care services alongside the drug, which enhances its appeal to employers [8][11] Market Position - Zepbound has become the leading weight loss drug, surpassing Novo Nordisk's Wegovy in sales and patient preference, despite the competitive landscape [4][12] - Eli Lilly's tirzepatide demonstrates approximately 20% average weight loss, compared to 14% for Novo Nordisk's semaglutide, giving it a significant competitive advantage [12] Competitive Landscape - Novo Nordisk is facing challenges, with a projected sales decline of 5% to 13% in 2026, while Eli Lilly anticipates robust growth [13] - The competition is intensifying as Novo Nordisk introduces its own oral semaglutide, but Eli Lilly's comprehensive care ecosystem and superior drug efficacy position it favorably [5][11] Future Outlook - Eli Lilly is set to launch oral tirzepatide in Q2 2026, which is expected to outperform Novo Nordisk's offerings in both weight loss and diabetes management [14] - Analysts predict that the Employer Connect program will significantly increase Zepbound's volume, with material sales contributions expected to ramp up in 2027 as more employers opt in [9][14]

Hello, I'm Ozmpic. >> GLP1s are everywhere. Micro do GLP1.From ripping through Hollywood, I'm on road to Super Bowl commercials. Many have called the drugs a medical miracle. >> It is in fact a miracle.>> In hopes of finally making progress in America's obesity crisis. And today, adding to the mounting evidence that these drugs could have benefits besides weight loss, a new study finding a 37% lower risk of death in patients with metastatic brain cancer. But the economic miracle that once seemed a sure bet, ...

Core Insights - SureNano Science Ltd. has acquired GlucaPharm Inc., enhancing its position in the pharmaceutical market focused on obesity and metabolic diseases with the development of GEP44, a next-generation glucagon-like peptide (GLP) [2][8] Company Overview - GlucaPharm is developing GEP44, a patented peptide that aims to provide weight reduction and blood glucose normalization with fewer side effects compared to existing GLP-1 drugs like Ozempic® and Wegovy® [5][10] - SureNano Science Ltd. is transitioning from an enabling-technology company to a pharmaceutical value creator, targeting the rapidly growing global drug market [2][8] Acquisition Details - The acquisition was structured as a share exchange, with SureNano issuing 8,100,999 common shares and warrants for 5,000,000 common shares to GlucaPharm shareholders [3] - The shares issued will have a hold period until certain conditions are met, including approval from the Canadian Securities Exchange [3] Leadership and Expertise - Dr. Nihar R. Pandey has been appointed as Director and Chief Scientific Officer, bringing over 25 years of experience in drug discovery and development [4] Product Development - GEP44 is expected to advance through an IND-enabling FDA study and Phase I Clinical Trial in Australia, with key milestones anticipated in the next six to nine months [7][9] - The global GLP market is currently dominated by injectable therapies, and GlucaPharm aims to develop non-injectable delivery methods to enhance patient adoption [6][9] Market Potential - The GLP-1 metabolic market is projected to be multi-hundred-billion dollars, and SureNano aims to position itself as a significant player alongside large pharmaceutical companies [9]

FDA's Marty Makary sits down with CNBC's Annika Kim Constantino to discuss the vaccine regulatory environment, compounding GLP-1 drugs and his efforts to change a large swath of prescription drugs to over-the-counter. He's looking at drugs such as vaginal estrogen and nausea medications to be available without a prescription. ...

The race to offer cheaper weight loss drugs is running into some legal limits. Tellahalth company Hims and Hers announced a cheaper version of Novo's Waggoi weight loss pill at the beginning of February. Now, it would cost $49 to start, which is far less than the $149 Novo sells the branded pill for, but it pulled the drug after legal and regulatory risks escalated.Now, legally, they're allowed to create a compounded version of a drug if they are saying they're adjusting the formula for quote personalized p ...

The race to offer cheaper weight loss drugs is running into some legal limits. Telehealth company Hims & Hers announced a cheaper version of Novo's Wegovy weight-loss pill at the beginning of February. Now it would cost $49 to start, which is far less than the $149 Novo sells the branded pill for.But it pulled the drug after legal and regulatory risks escalated. Now, legally, they're allowed to create a compounded version of a drug if they are saying they're adjusting the formula for "personalized purposes. ...